Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma

May 29-31, 2020; Online at meetings.asco.org/am
Idecabtagene vicleucel therapy resulted in CR/sCR responses in one third of patients with heavily pretreated R/R MM with durability approaching 2 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

Free video from Clinical Care Options featuring expert discussion of the latest updates in CAR T-cell therapy for hematologic cancers

Michael R. Bishop, MD
Program Director
Daniel J. DeAngelo, MD, PhD Noopur Raje, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s) Released: August 14, 2020 Expired: August 13, 2021

From Clinical Care Options (CCO), watch this video featuring expert presentations on new and emerging biomarkers key to lung cancer care

Edward S. Kim, MD, FACP
Program Director
Leora Horn, MD, MSc, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: July 30, 2020 Expired: July 29, 2021

From Clinical Care Options (CCO), watch this video featuring expert nurse perspectives on new and emerging biomarkers critical to the care of patients with cancer

Elisabeth King, RN, FNP, AGN, AOCNP
Program Director
person default Diane Cope, PhD, ARNP-BC, AOCNP Sara Toth, RN, MSN, FNP-C, AOCNP, AGN-BC
Registered Nurses: 1.75 Nursing contact hours Released: July 21, 2020 Expired: July 20, 2021

Gain key clinical insights fast, with this short slideset from CCO on biomarkers for imuno-onolcogy approaches across solid tumors

Jamie E. Chaft, MD John L. Marshall, MD Scot Niglio, MD Released: July 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?